All In Biotech

Drug Trial Radar · NCT03085095

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

Last checked: Nov 20, 2026Latest source record: Jan 18, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,134 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,134

Actual

Start

Apr 18, 2017

Primary completion

Oct 25, 2019

Study completion Nov 26, 2021

Sponsor

Lead sponsor
Myovant Sciences GmbHIndustry
Sponsor type
Industry
First posted
Mar 21, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the efficacy and safety of relugolix 120 milligrams (mg) orally once daily for 48 weeks on maintaining serum testosterone suppression to castrate levels (\< 50 nanograms/deciliter \[ng/dL\]) in participants with androgen-sensitive advanced prostate cancer.

Conditions

  • Prostate Cancer

Interventions

  • RelugolixDrug

    Relugolix 120-mg tablet administered orally once daily following an oral loading dose of 360 mg (3 x 120-mg tablets) on Day 1

  • Leuprolide AcetateDrug

    Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in Japan, Taiwan, and China), every 3 months by subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sustained Castration RateTime frame: From Week 5 Day 1 (Day 29) to Week 49 Day 1 (Day 337)

Locations

162 sites in 22 countries. Site status is shown where the registry gives one.

  • Tucson

    Tucson, Arizona

  • Orange

    Orange, California

  • Denver

    Denver, Colorado

  • Pompano Beach

    Pompano Beach, Florida

  • Jeffersonville

    Jeffersonville, Indiana

  • Des Moines

    Des Moines, Iowa

  • Wichita

    Wichita, Kansas

  • Baltimore

    Baltimore, Maryland

  • Troy

    Troy, Michigan

  • Omaha

    Omaha, Nebraska

  • Las Vegas

    Las Vegas, Nevada

  • Brick

    Brick, New Jersey

  • Albuquerque

    Albuquerque, New Mexico

  • Albany

    Albany, New York

  • Garden City

    Garden City, New York

  • Plainview

    Plainview, New York

  • Poughkeepsie

    Poughkeepsie, New York

  • Syracuse

    Syracuse, New York

  • Durham

    Durham, North Carolina

  • Greensboro

    Greensboro, North Carolina

  • Cincinnati

    Cincinnati, Ohio

  • Middleburg Heights

    Middleburg Heights, Ohio

  • Oklahoma City

    Oklahoma City, Oklahoma

  • Lancaster

    Lancaster, Pennsylvania

  • Myrtle Beach

    Myrtle Beach, South Carolina

  • Nashville

    Nashville, Tennessee

  • San Antonio

    San Antonio, Texas

  • Camperdown

    Camperdown, New South Wales, Australia

  • Tweed Heads

    Tweed Heads, New South Wales, Australia

  • Wahroonga

    Wahroonga, New South Wales, Australia

  • Redcliffe

    Redcliffe, Queensland, Australia

  • Southport

    Southport, Queensland, Australia

  • Linz

    Linz, Austria

  • Brussels

    Brussels, Belgium

  • Kortrijk

    Kortrijk, Belgium

  • Gent

    Ghent, Oost-Vlaanderen, Belgium

  • Curitiba

    Curitiba, Brazil

  • Itabuna

    Itabuna, Estado de Bahia, Brazil

  • Salvador

    Salvador, Estado de Bahia, Brazil

  • Salvador

    Salvador, Estado de Bahia, Brazil

Showing 40 of 162 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.